4//SEC Filing
Gelbfish Gary A. 4
Accession 0001654954-18-001718
CIK 0001410098other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 4:03 PM ET
Size
16.6 KB
Accession
0001654954-18-001718
Insider Transaction Report
Form 4
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
- Award
Stock Option (Right to Buy Common Stock)
2018-02-16+40,000→ 40,000 totalExercise: $0.57Exp: 2028-02-16→ Common Stock (40,000 underlying) - Award
Restricted Stock Units
2018-02-16+10,000→ 10,000 total→ Common Stock (10,000 underlying)
Holdings
- 75,000
Stock Option (Right to Buy Common Stock)
Exercise: $0.37Exp: 2027-08-03→ Common Stock, $0.001 par value per share (75,000 underlying) - 250,000
Warrant (Right to Purchase Common Stock)
Exercise: $0.90From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (250,000 underlying) - 2,101,121
Common Stock
- 14,000(indirect: By Foundation)
Common Stock
- 50,000
Series C-3 Non-Voting Convertible Preferred Stock
From: 2014-01-08→ Common Stock, $0.001 par value per share (500,000 underlying) - 1,000,000
Series A Common Stock Warrant
Exercise: $0.75→ Common Stock, $0.001 par value per share (1,000,000 underlying) - 1,000,000
Series B Common Stock Warrant
Exercise: $1.05→ Common Stock, $0.001 par value per share (1,000,000 underlying)
Footnotes (7)
- [F1]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
- [F2]These options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
- [F3]Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock vests in full on the first anniversary of the date of grant, subject to continued service on the board.
- [F4]These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
- [F5]The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
- [F6]The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date.
- [F7]The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.
Documents
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeother
Related Parties
1- filerCIK 0001488011
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 4:03 PM ET
- Size
- 16.6 KB